Canopy Growth (CGC)
(Delayed Data from NSDQ)
$6.21 USD
+0.07 (1.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.21 USD
+0.07 (1.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Canopy Growth Corporation (CGC) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Canopy Growth (CGC) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
Pot Stocks Take Markets Higher; Plus Beats for Cisco, Twitter, Lyft
by Mark Vickery
With Tilray (TLRY) +44% and Canopy (CGC) +12% on the day, the Nasdaq and Russell 2000 managed to climb to fresh all-time highs Tuesday.
Canopy Growth Corporation (CGC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -366.67% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $44.14 in the latest trading session, marking a -1.78% move from the prior day.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
Canopy Growth (CGC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal third quarter.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cannabis ETF Tops in January: 5 Stocks That Led the Way
by Sweta Killa
Inside the top performing stocks in the top ETF of January.
Canopy Growth Corporation (CGC) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $40.07, marking a -0.64% move from the previous day.
Investing Strategies to Follow on Democratic Senate and House
by Sanghamitra Saha
Democratic taking control of both House and Senate, these investing strategies should prosper in the coming days.
The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ
4 Stocks to Ride the Wave of Cannabis Legalization
by Nitish Marwah
Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $25.54, moving -1.66% from the previous trading session.
ETFs to Buy as Tilray-Aphria Merger Creates Cannabis Giant
by Sweta Killa
Investors seeking to take advantage of the merger deal between Tilray and Aphria could invest in any of the cannabis ETFs.
Should You Buy Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.
Company News for Nov 10, 2020
by Zacks Equity Research
Companies In The News Are: MCD, GSK, PRTY, CGC
Should You Buy Canopy Growth (CGC) Ahead of Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Canopy Growth (CGC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal second quarter.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.